Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Modulation of Leukotriene Signaling Affecting Cell Growth in Chronic Myeloid Leukemia: A Key Pathway to Cure?

Elham Yektaei, PhD, Anders Nilsson, PhD, Barbro Näsman-Glaser, MSc, Marja Ekblom, MD PhD, Hong Qian, PhD, Olof Rådmark, PhD, Ana Zovko, PhD, Lena Kanter, MD PhD, Jonas Wallvik, MD PhD, Leif Stenke, MD PhD

Blood (2015) 126 (23): 5137.

https://doi.org/10.1182/blood.V126.23.5137.5137

Published: 2015

Journal Articles

Second Malignancies Following Treatment of Chronic Myeloid Leukemia in the Tyrosine Kinase Inhibitor Era

Niklas Gunnarsson, MD, Stenke Leif, MD PhD, Martin Höglund, MD PhD, Fredrik Sandin, PhD, Magnus Björkholm, MD PhD, Arta Dreimane, MD PhD, Mats Lambe, MD PhD, Berit Markevärn, MD, Ulla Olsson-Strömberg, MD PhD, Johan Richter, MD PhD, Hans Wadenvik, MD PhD, Jonas Wallvik, MD PhD, Anders Själander, MD PhD

Blood (2014) 124 (21): 154.

https://doi.org/10.1182/blood.V124.21.154.154

Published: 2014

Journal Articles

Maintenance Treatment with 5-Azacitidine for Patients with High Risk Myelodysplastic Syndr–ome (MDS) or Acute Myeloid Leukemia Following MDS (MDS-AML) in Complete Remission (CR) after Induction Chemotherapy

Michael Grövdal, Rasheed Khan, Anni Aggerholm, Petar Antunovic, Jan Astermark, Per Bernell, Lena-Maria Engström, Lars Kjeldsen, Olle Linder, Lars Nilsson, Anna Olsson, Jonas Wallvik, Jon Magnus Tangen, Gunnar Öberg, Sten Eirik Jacobsen, Anna Porwit, Peter Hokland, Eva Hellström-Lindberg

Blood (2008) 112 (11): 223.

https://doi.org/10.1182/blood.V112.11.223.223

Published: 2008

Journal Articles

Maintenance Treatment with Azacytidine for Patients with High Risk Myelodysplastic Syndromes or Acute Myeloid Leukaemia in Complete Remission after Intensive Chemotherapy.

Michael Grövdal, Rasheed Khan, Anni Aggerholm, Petar Antunovic, Jan Astermark, Per Bernell, Lena-Maria Engström, Lars Kjeldsen, Olle Linder, Lars Nilsson, Anna Olsson, Jonas Wallvik, Jon Magnus Tangen, Gunnar Öberg, Sten Eirik Jacobsen, Peter Hokland, Anna Porwit, Eva Hellström-Lindberg

Blood (2007) 110 (11): 818.

https://doi.org/10.1182/blood.V110.11.818.818

Published: 2007

Journal Articles

Cladribine (CdA) or Fludarabine (F) or High-Dose Intermittent Chlorambucil (Chl) as First-Line Treatment of Symptomatic Chronic Lymphocytic Leukemia? First Interim Analysis of Data from the International Randomized Phase III Trial.

Karin Karlsson, Mats Strömberg, Viggo Jönsson, Devinder Gill, Jens Hammerström, Jonas Wallvik, Stephen Mulligan, Kenneth Bradstock, Jan Liliemark, Gunnar Juliusson

Blood (2004) 104 (11): 3470.

https://doi.org/10.1182/blood.V104.11.3470.3470

Published: 2004

NARROW

Modulation of Leukotriene Signaling Affecting Cell Growth in Chronic Myeloid Leukemia: A Key Pathway to Cure?

Second Malignancies Following Treatment of Chronic Myeloid Leukemia in the Tyrosine Kinase Inhibitor Era

Maintenance Treatment with 5-Azacitidine for Patients with High Risk Myelodysplastic Syndr–ome (MDS) or Acute Myeloid Leukemia Following MDS (MDS-AML) in Complete Remission (CR) after Induction Chemotherapy

Maintenance Treatment with Azacytidine for Patients with High Risk Myelodysplastic Syndromes or Acute Myeloid Leukaemia in Complete Remission after Intensive Chemotherapy.

Cladribine (CdA) or Fludarabine (F) or High-Dose Intermittent Chlorambucil (Chl) as First-Line Treatment of Symptomatic Chronic Lymphocytic Leukemia? First Interim Analysis of Data from the International Randomized Phase III Trial.

Email alerts

ASH Publications

American Society of Hematology

Modulation of Leukotriene Signaling Affecting Cell Growth in Chronic Myeloid Leukemia: A Key Pathway to Cure?

Second Malignancies Following Treatment of Chronic Myeloid Leukemia in the Tyrosine Kinase Inhibitor Era

Maintenance Treatment with 5-Azacitidine for Patients with High Risk Myelodysplastic Syndr–ome (MDS) or Acute Myeloid Leukemia Following MDS (MDS-AML) in Complete Remission (CR) after Induction Chemotherapy

Maintenance Treatment with Azacytidine for Patients with High Risk Myelodysplastic Syndromes or Acute Myeloid Leukaemia in Complete Remission after Intensive Chemotherapy.

Cladribine (CdA) or Fludarabine (F) or High-Dose Intermittent Chlorambucil (Chl) as First-Line Treatment of Symptomatic Chronic Lymphocytic Leukemia? First Interim Analysis of Data from the International Randomized Phase III Trial.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only